| Popis: |
Lesia V Tchobaniouk,1 Erin E McAllister,2 Danielle L Bishop,3 Rachel M Carpentier,4 Katharine R Heins,4 Robert J Haight,5 Jeffrey R Bishop6,7 1Department of Pharmacy, North Memorial Health Hospital, Robbinsdale, MN, USA; 2Department of Pharmacy, Clement J. Zablocki VA Medical Center, Milwaukee, WI, USA; 3Department of Pharmacy, M Health Fairview St. Joseph’s Hospital, St. Paul, MN, USA; 4Department of Pharmacy, Fairview Pharmacy Services, Minneapolis, MN, USA; 5Pharmacy Services, University of Minnesota Medical Center, Minneapolis, MN, USA; 6Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA; 7Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, MN, USACorrespondence: Jeffrey R BishopDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USAEmail jrbishop@umn.eduAbstract: Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral formulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risperidone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.Keywords: adherence, long-acting injections, antipsychotic medications, RBP-7000, risperidone |
